Nuvation Bio Inc - Class A. Every tracked FinTwit mention of $NUVB, newest first. 10 mentions since the first on Jun 12, 2025. See the price chart.
June 2025 · 10 mentions
Jun 24
Jacob Plieth — And here's your handy $NUVL vs $NUVB X-trial comparison (note caveats) https://t.co/HgHxFZio6C↗
Jun 24
Jacob Plieth — $NUVL tries to match $NUVB, but zidesamtinib has lost important ground in the front line. @ApexOnco take on the Arros-1 update, plus filing plans -> https://t.co/JG83lbhPkq↗
Jun 24
Jacob Plieth — Today it's $NUVL's turn with its ROS1-selective inhibitor zidesamtinib. Arros-1 data out by PR at 6:30am ET, then investor call at 8am. $NUVB↗
Jun 12
Jacob Plieth — $NUVB -10%, mkt cap $670m
$NUVL +1%, mkt cap $5.5bn↗
Jun 12
Jacob Plieth — @msp12389 I think the word you're looking for is cynical! But I've been around long enough to know that no biotech is a charity, and I'm sure $NUVB is no exception.↗
Jun 12
Jacob Plieth — @msp12389 Why would $NUVB even bother losing money by promoting this? Small market, plus they've already monetized Ibtrozi (Sagard deal), so zero incentive for them to do so. And t…↗
Jun 12
Jacob Plieth — @BiotechObserver @oncinvestor Precisely $NUVB https://t.co/q05znyQpQY↗
Jun 12
Jacob Plieth — Surprising that $NUVB Ibtrozi has been allowed as the tradename. Fairly similar to $RHHBY Itovebi, no?↗
Jun 12
Jacob Plieth — @oncinvestor @BiotechObserver From $NUVB. Is this selectivity enough? 🧐 https://t.co/gmip7mrcN0↗
Jun 12
Jacob Plieth — $NUVB still claiming that Ibtrozi (taletrectinib) is a "next-generation Ros1 inhibitor", but this is what the FDA says: $NUVL https://t.co/dWd3WYf0cJ↗